Hair Repigmentation With Anti-PD-1 and Anti-PD-L1 Immunotherapy: A Novel Hypothesis

Guillaume Manson (1) , Aurélien Marabelle (2, 3) , Roch Houot (4)

1 CHU Pontchaillou [Rennes]
2 DITEP - Département d’Innovation Thérapeutique et essais précoces [Gustave Roussy]
3 UMR 1015 - Immunologie des tumeurs et immunothérapie
4 MICMAC - Microenvironment, Cell Differentiation, Immunology and Cancer

The article by Rivera et al is the first report of a previously undescribed side effect of checkpoint inhibitors: hair repigmentation (HR). In this significant case series of 14 patients, all patients received an anti–programmed cell death 1 (PD-1) and anti–programmed cell death 1 ligand 1 (PD-L1) antibody for the treatment of a lung cancer...

Domains: Life Sciences [q-bio]; Immunology; Immunotherapy; Life Sciences [q-bio]; Human health and pathology; Dermatology; Life Sciences [q-bio]; Cancer

Guillaume Manson, Aurélien Marabelle, Roch Houot. Hair Repigmentation With Anti-PD-1 and Anti-PD-L1 Immunotherapy: A Novel Hypothesis. Journal of the American Medical Association, 2018, 154 (1), pp.113. ⟨10.1001/jamadermatol.2017.4421⟩. ⟨hal-01699247⟩